OSE Immunotherapeutics Reports Positive Topline Results From Combi-TED Phase 2 Trial
OSE Immunotherapeutics reported positive topline results from its randomized Phase 2 Combi-TED trial of Tedopi in metastatic non-small cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.